Furfaro, A.L.; Loi, G.; Ivaldo, C.; Passalacqua, M.; Pietra, G.; Mann, G.E.; Nitti, M.
HO-1 Limits the Efficacy of Vemurafenib/PLX4032 in BRAFV600E Mutated Melanoma Cells Adapted to Physiological Normoxia or Hypoxia. Antioxidants 2022, 11, 1171.
https://doi.org/10.3390/antiox11061171
AMA Style
Furfaro AL, Loi G, Ivaldo C, Passalacqua M, Pietra G, Mann GE, Nitti M.
HO-1 Limits the Efficacy of Vemurafenib/PLX4032 in BRAFV600E Mutated Melanoma Cells Adapted to Physiological Normoxia or Hypoxia. Antioxidants. 2022; 11(6):1171.
https://doi.org/10.3390/antiox11061171
Chicago/Turabian Style
Furfaro, Anna Lisa, Giulia Loi, Caterina Ivaldo, Mario Passalacqua, Gabriella Pietra, Giovanni Enrico Mann, and Mariapaola Nitti.
2022. "HO-1 Limits the Efficacy of Vemurafenib/PLX4032 in BRAFV600E Mutated Melanoma Cells Adapted to Physiological Normoxia or Hypoxia" Antioxidants 11, no. 6: 1171.
https://doi.org/10.3390/antiox11061171
APA Style
Furfaro, A. L., Loi, G., Ivaldo, C., Passalacqua, M., Pietra, G., Mann, G. E., & Nitti, M.
(2022). HO-1 Limits the Efficacy of Vemurafenib/PLX4032 in BRAFV600E Mutated Melanoma Cells Adapted to Physiological Normoxia or Hypoxia. Antioxidants, 11(6), 1171.
https://doi.org/10.3390/antiox11061171